Affimed NV (NASDAQ:AFMD)’s share price rose 2% on Wednesday . The company traded as high as $4.25 and last traded at $4.07. Approximately 67,407 shares traded hands during trading, a decline of 85% from the average daily volume of 438,131 shares. The stock had previously closed at $3.99.
AFMD has been the subject of a number of research analyst reports. ValuEngine cut shares of Affimed from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Zacks Investment Research upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Thursday, January 3rd. Finally, BidaskClub upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $4.81.
The company has a current ratio of 3.66, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $249.56 million, a price-to-earnings ratio of -5.15 and a beta of 3.39.
Affimed Company Profile (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: How to invest in a bear market
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.